← Back to Search
Characterization Of Highly Immunogenic P66/p51 As The Reverse Transcriptase Of HTLV-III/LAV.
F. di Marzo Veronese, T. Copeland, A. Devico, R. Rahman, S. Oroszlan, R. Gallo, M. Sarngadharan
Published 1986 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Approximately 80 percent of all human sera that react with antigens of HTLV-III, the etiologic agent of the acquired immune deficiency syndrome (AIDS), recognize protein bands at 66 and 51 kilodaltons. A mouse hybridoma was produced that was specific to these proteins. Repeated cloning of the hybridoma did not separate the two reactivities. The p66/p51 was purified from HTLV-III lysates by immunoaffinity chromatography and subjected to NH2-terminal Edman degradation. Single amino acid residues were obtained in 17 successive degradation cycles. The sequence determined was a perfect translation of the nucleotide sequence of a portion of the HTLV-III pol gene. The purified p66/51 had reverse transcriptase activity and the monoclonal immunoglobulin G specifically removed the enzyme activity from crude viral extract as well as purified enzyme.
This paper references
Mechanism of action of Moloney murine leukemia virus RNA-directed DNA polymerase associated RNase H (RNase H I).
G. Gerard (1981)
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.
J. Allan (1985)
Separation of amino acid phenylthiohydantoins by high-performance liquid chromatography on phenylalkyl support.
L. Henderson (1980)
Theory and methods for immunization in culture and monoclonal antibody production.
C. Reading (1982)
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.
F. D. M. Veronese (1985)
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H. Mitsuya (1985)
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
M. Popovič (1984)
Amino- and carboxyl-terminal sequence of Moloney murine leukemia virus reverse transcriptase.
T. Copeland (1985)
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.
H. Mitsuya (1984)
Complete nucleotide sequence of the AIDS virus, HTLV-III
L. Ratner (1985)
Endonuclease activity of purified RNA-directed DNA polymerase from avian myeloblastosis virus.
M. Golomb (1979)
Amino acid sequence analysis of reverse transcriptase subunits from avian myeloblastosis virus.
T. Copeland (1980)
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.
W. Robey (1985)
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.
M. Sarngadharan (1984)
A gas-liquid solid phase peptide and protein sequenator.
R. Hewick (1981)
Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources.
S. Salahuddin (1985)
This paper is referenced by
Antibodies to reverse transcriptase in HIV infection and progression to AIDS.
A. Schattner (1992)
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
S. Layne (1992)
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
P. L. Boyer (1994)
Functional characteristics of a reverse transcriptase encoded by an endogenous retrovirus from Drosophila melanogaster.
F. Arnaud (2005)
HIV-1 reverse transcription: close encounters between the viral genome and a cellular tRNA.
T. E. Abbink (2007)
HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies
V. Georgiev (2009)
Multiple nucleotide preferences determine cleavage-site recognition by the HIV-1 and M-MuLV RNases H.
S. Schultz (2010)
Targeting Small Molecules and Peptides to the p66-p51 Reverse Transcriptase Interface
Daouda Mousatpha Abba Moussa (2013)
MODULATION OF HIV-1 REVERSE TRANSCRIPTASE AND FAMILY A DNA POLYMERASE PRIMER-TEMPLATE BINDING
Katherine J Fenstermacher (2014)
Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells
A. Davis (2008)
Chaotic dynamics of fractional Vallis system for El-Nino
Amey S Deshpande (2018)
An anti-p24 monoclonal antibody shows cross-reactivity with multiple HIV-1 proteins.
C. Liang (1990)
Activity Profiles & Mechanisms of Resistance of 3'-Azido-2',3'-Dideoxynucleoside Analog Reverse Transcriptase Inhibitors of HIV-1
Jeffrey D Meteer (2013)
Recombinant polypeptides from the human immunodeficiency virus reverse transcriptase define three epitopes recognized by antibodies in sera from patients with acquired immunodeficiency syndrome.
C. Padberg (1989)
Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities.
V. Mizrahi (1989)
Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications.
J. Ongrádi (1990)
The Road to Fortovase. A History of Saquinavir, the First Human Immunodeficiency Virus Protease Inhibitor
S. Redshaw (2000)
Comparison of Second-Strand Transfer Requirements and RNase H Cleavages Catalyzed by Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) and E478Q RT
C. Snyder (2000)
Cross-sectional study of reverse transcriptase-inhibiting antibody as a marker of acquired immune deficiency syndrome.
M. Advani (1989)
Analysis of HIV-1 gag matrix and capsid domain mutations and their effects on virus assembly and infectivity
Isabel Scholz (2007)
HIV ribonuclease H: continuing the search for small molecule antagonists.
Michaela Wendeler (2009)
HIV-1-Inhibiting Viral Protein Mutants Type 1 (HIV-1) Variant: Identification of Novel Nonproducer Human Immunodeficiency Virus Homologous Viral Interference Induced by a gag, vif, and nef Genes Contribute to the
Maurizio Federico (2013)
HIV reverse transcriptase structure-function relationships.
A. Jacobo-Molina (1991)
Review of HIV-1 reverse transcriptase three-dimensional structure : implications for drug design
R. G. Nanni (1993)
HIV-1 reverse transcriptase: polymerization properties of the p51 homodimer compared to the p66/p51 heterodimer.
M. R. Bavand (1993)
The Formation of the 2′,5′-Phosphodiester Linkage in the cDNA Priming Reaction by Bacterial Reverse Transcriptase in a Cell-free System (*)
T. Shimamoto (1995)
HIV-1 protease inhibits its homologous reverse transcriptase by protein-protein interaction.
M. Böttcher (1997)
Analysis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Subunit Structure/Function in the Context of Infectious Virions and Human Target Cells
Alok Mulky (2005)
A New Generation of Peptide-based Inhibitors Targeting HIV-1 Reverse Transcriptase Conformational Flexibility*
A. Agopian (2009)
A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation.
B. Sharma (2003)
Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer
Paola Sinibaldi-Vallebona (2011)
Coat protein of cauliflower mosaic virus binds to ssDNA
Sunnie R. Thompsont (2007)See more